New hope for cystic fibrosis diabetes: GLP-1 drug shows promise in small study
NCT ID NCT05788965
First seen Feb 01, 2026 · Last updated Apr 25, 2026 · Updated 13 times
Summary
This small pilot study tested a GLP-1 medication (semaglutide) added to insulin in 8 overweight adults with cystic fibrosis-related diabetes. The main goals were to see if the drug is safe and helps with weight loss and blood sugar control. Results will guide future research on managing this complex condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.